Zomedica Pharmaceuticals Corp Stock Earnings Per Share
| ZOM Stock | USD 0.12 0 2.50% |
Zomedica Pharmaceuticals Corp fundamentals help investors to digest information that contributes to Zomedica Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zomedica Stock. The fundamental analysis module provides a way to measure Zomedica Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zomedica Pharmaceuticals stock.
Zomedica | Earnings Per Share |
Zomedica Pharmaceuticals Corp Company Earnings Per Share Analysis
Zomedica Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Zomedica Pharmaceuticals Earnings Per Share | (0.06) X |
Most of Zomedica Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zomedica Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zomedica Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Zomedica Pharmaceuticals is extremely important. It helps to project a fair market value of Zomedica Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Zomedica Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zomedica Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zomedica Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Zomedica Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Zomedica Pharmaceuticals Corp has an Earnings Per Share of -0.06 times. This is 100.72% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The earnings per share for all United States stocks is 101.92% higher than that of the company.
Zomedica Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zomedica Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zomedica Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zomedica Pharmaceuticals by comparing valuation metrics of similar companies.Zomedica Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Zomedica Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Zomedica Pharmaceuticals from analyzing Zomedica Pharmaceuticals' financial statements. These drivers represent accounts that assess Zomedica Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zomedica Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 35.2M | 84.0M | 293.2M | 159.7M | 196.2M | 206.0M | |
| Enterprise Value | 34.7M | 23.9M | 99.6M | 134.1M | 186.0M | 195.3M |
Zomedica Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0929 | ||||
| Profit Margin | (2.15) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 47.11 M | ||||
| Shares Outstanding | 997.95 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 8.33 % | ||||
| Number Of Shares Shorted | 51.14 M | ||||
| Price To Book | 0.60 X | ||||
| Price To Sales | 4.67 X | ||||
| Revenue | 25.19 M | ||||
| Gross Profit | 13.65 M | ||||
| EBITDA | (29.39 M) | ||||
| Net Income | (34.53 M) | ||||
| Cash And Equivalents | 27.4 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 2.73 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 43.50 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (15.97 M) | ||||
| Short Ratio | 17.24 X | ||||
| Earnings Per Share | (0.06) X | ||||
| Target Price | 0.25 | ||||
| Number Of Employees | 144 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 147.6 M | ||||
| Total Asset | 253.2 M | ||||
| Retained Earnings | (170.93 M) | ||||
| Working Capital | 90.85 M | ||||
| Net Asset | 253.2 M |
About Zomedica Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zomedica Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zomedica Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zomedica Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Zomedica Pharmaceuticals Piotroski F Score and Zomedica Pharmaceuticals Altman Z Score analysis. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.